NIFTY 50 23415.15 ▲ (0.3%)
NIFTY NEXT 50 65001.65 ▼ (0.16%)
NIFTY 100 24101.2 ▲ (0.22%)
NIFTY MIDCAP 100 55118.45 ▲ (0.02%)
NIFTY SMALLCAP 100 17936.45 ▲ (0.4%)
NIFTY SMALLCAP 250 16918.6 ▲ (0.46%)
NIFTY MIDCAP SELECT 12325.1 ▼ (0.25%)
NIFTY TOTAL MARKET 12335.95 ▲ (0.25%)
NIFTY BANK 49318.85 ▼ (0.06%)
SENSEX 77176.46 ▲ (0.13%)
BSE BANKEX 55964.97 ▼ (0.13%)

KOBO BIOTECH : Q4 2024 Financial Quarterly Report

July 2, 2024July 2, 2024| adminadmin| 0 Comments| 5:50 pm
Image is loading
Categories:

Share the post "KOBO BIOTECH : Q4 2024 Financial Quarterly Report"

  • Facebook
  • LinkedIn
  • X
  • Tumblr
  • WhatsApp
  • TelegramTelegram
  • Email

Highlights

  • Sales over the Year and quarter:
  • Income over the Year and quarter:
  • Profit over the Year and quarter: Challenges in sustaining profitability for KOBO BIOTECH LIMITED. Profit dropped by -29.95 % Year to Year, KOBO BIOTECH LIMITED’s profitability increased by 2.03 % in this quarter.
  • EPS over the Year and quarter: EPS declined by -29.33 % Year to Year. EPS increased by 1.92 % in previous quarter. Positive impact on shareholders.

The comprehensive analytics outlining the performance and outlook of KOBO BIOTECH LIMITED”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 0 Cr Rs. 0 Cr Rs. 0 Cr 0 % 0 %
Expenses Rs. 0.79 Cr Rs. 0.2 Cr Rs. 0.25 Cr + 25 % -68.35 %
Operating Profit Rs. -0.79 Cr Rs. -0.2 Cr Rs. -0.25 Cr -25 % + 68.35 %
OPM % 0 % 0 % 0 % 0 % 0 %
Other Income Rs. 0 Cr Rs. 0 Cr Rs. -0 Cr 0 % 0 %
Interest Rs. 0 Cr Rs. 0 Cr Rs. 0 Cr 0 % 0 %
Depreciation Rs. 1 Cr Rs. 1.03 Cr Rs. 1.01 Cr -1.94 % + 1 %
Profit before tax Rs. -1.79 Cr Rs. -1.23 Cr Rs. -1.26 Cr -2.44 % + 29.61 %
Tax % -0 % -0 % -0 % 0 % 0 %
Net Profit Rs. -1.79 Cr Rs. -1.23 Cr Rs. -1.26 Cr -2.44 % + 29.61 %
EPS in Rs Rs. -0.75 Rs. -0.52 Rs. -0.53 -1.92 % + 29.33 %


Today, we’re looking at KOBO BIOTECH LIMITED’s financial performance for the Q4(Mar 2024).Expenses ticked up slightly by 25 % quarter-on-quarter, aligning with the annual decline of -68.35 %. Operating profit, while up 68.35 % compared to last year, faced a quarter-on-quarter dip of -25 %, signaling a short-term contraction in margins.
Depreciation costs fell by -1.94 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 1 %. Profit before tax grew annually by 29.61 % but saw a reduction from the preceding quarter by -2.44 %.
Net profit rose by 29.61 % year-on-year but witnessed a -2.44 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 29.33 % but a quarterly fall of -1.92 %. In summary, KOBO BIOTECH LIMITED’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 0 Cr Rs. 0 Cr Rs. 0 Cr 0 % 0 %
Expenses Rs. 0.79 Cr Rs. 0.2 Cr Rs. 0.25 Cr + 25 % -68.35 %
Operating Profit Rs. -0.79 Cr Rs. -0.2 Cr Rs. -0.25 Cr -25 % + 68.35 %
Net Profit Rs. -1.79 Cr Rs. -1.23 Cr Rs. -1.26 Cr -2.44 % + 29.61 %
EPS in Rs Rs. -0.75 Rs. -0.52 Rs. -0.53 -1.92 % + 29.33 %


In reviewing KOBO BIOTECH LIMITED’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Expenses decreased by -68.35 % compared to the previous year, with a 25 % increase quarter-on-quarter. Operating Profit surged by 68.35 % annually, and saw a -25 % decrease from the last quarter.
Net Profit showed yearly increase of 29.61 %, and experienced a -2.44 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 29.33 % annually, however dipped by -1.92 % compared to the last quarter. In essence, while KOBO BIOTECH LIMITED exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.

[my_shortcode1 values=”KOBO BIOTECH “]

Related Post